Verrica Pharmaceuticals Inc. Selling, General and Administrative Expense
Verrica Pharmaceuticals Inc. (VRCA) reported Selling, General and Administrative Expense of $10.35 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-06
- Verrica Pharmaceuticals Inc. selling, general and administrative expense for the quarter ending 2026-06-30 was $10.35M, a 16.91% increase year-over-year.
- Verrica Pharmaceuticals Inc. selling, general and administrative expense for the quarter ending 2026-03-31 was $9.99M, a 12.90% increase year-over-year.
- Verrica Pharmaceuticals Inc. selling, general and administrative expense for the quarter ending 2025-12-31 was $8.12M, a 17.83% decline year-over-year.
- Verrica Pharmaceuticals Inc. selling, general and administrative expense for the quarter ending 2025-09-30 was $9.40M, a 41.53% decline year-over-year.
- Verrica Pharmaceuticals Inc. selling, general and administrative expense for fiscal 2025 was $35.22M, a 40.12% decline from fiscal 2024.
- Verrica Pharmaceuticals Inc. selling, general and administrative expense for fiscal 2024 was $58.82M, a 24.35% increase from fiscal 2023.
- Verrica Pharmaceuticals Inc. selling, general and administrative expense for fiscal 2023 was $47.30M, a 171.79% increase from fiscal 2022.
- Verrica Pharmaceuticals Inc. selling, general and administrative expense for fiscal 2022 was $17.41M.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 9 month as first filed | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $10.35M 10-Q · filed 2026-08-06 | $20.34M 10-Q · filed 2026-08-06 | $28.45M derived: sum of 3 quarters · filed 2026-08-06 | $37.86M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2026-03-31 | $9.99M 10-Q · filed 2026-05-12 | $18.11M derived: sum of 2 quarters · filed 2026-05-12 | $27.51M derived: sum of 3 quarters · filed 2026-05-12 | $36.36M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-12-31 | $8.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $17.52M derived: sum of 2 quarters · filed 2026-03-11 | $26.37M derived: sum of 3 quarters · filed 2026-08-06 | $35.22M 10-K · filed 2026-03-11 | |
| 2025-09-30 | $9.40M 10-Q · filed 2025-11-14 | $18.25M derived: sum of 2 quarters · filed 2026-08-06 | $27.10M 10-Q · filed 2025-11-14 | $36.98M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-06-30 | $8.85M 10-Q · filed 2026-08-06 | $17.70M 10-Q · filed 2026-08-06 | $27.58M derived: sum of 3 quarters · filed 2026-08-06 | $43.66M derived: sum of 4 quarters · filed 2026-08-06 | |
| 2025-03-31 | $8.85M 10-Q · filed 2026-05-12 | $18.73M derived: sum of 2 quarters · filed 2026-05-12 | $34.81M derived: sum of 3 quarters · filed 2026-05-12 | $51.33M derived: sum of 4 quarters · filed 2026-05-12 | |
| 2024-12-31 | $9.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-11 | $25.96M derived: sum of 2 quarters · filed 2026-03-11 | $42.48M derived: sum of 3 quarters · filed 2026-03-11 | $58.82M 10-K · filed 2026-03-11 | |
| 2024-09-30 | $16.08M 10-Q · filed 2025-11-14 | $32.60M derived: sum of 2 quarters · filed 2025-11-14 | $48.94M 10-Q · filed 2025-11-14 | $48.94M 10-Q · filed 2024-11-05 | $65.94M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | $16.52M 10-Q · filed 2025-08-12 | $32.86M 10-Q · filed 2025-08-12 | $49.86M derived: sum of 3 quarters · filed 2025-08-12 | $69.91M derived: sum of 4 quarters · filed 2025-08-12 | |
| 2024-03-31 | $16.34M 10-Q · filed 2025-05-13 | $33.33M derived: sum of 2 quarters · filed 2025-05-13 | $53.39M derived: sum of 3 quarters · filed 2025-05-13 | $59.33M derived: sum of 4 quarters · filed 2025-05-13 | |
| 2023-12-31 | $17.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $37.05M derived: sum of 2 quarters · filed 2025-03-11 | $42.99M derived: sum of 3 quarters · filed 2025-03-11 | $47.30M 10-K · filed 2025-03-11 | |
| 2023-09-30 | $20.05M 10-Q · filed 2024-11-05 | $25.99M derived: sum of 2 quarters · filed 2024-11-05 | $30.31M 10-Q · filed 2024-11-05 | $33.50M derived: sum of 4 quarters · filed 2024-11-05 | |
| 2023-06-30 | $5.94M 10-Q · filed 2024-08-14 | $10.26M 10-Q · filed 2024-08-14 | $13.45M derived: sum of 3 quarters · filed 2024-08-14 | $17.37M derived: sum of 4 quarters · filed 2024-08-14 | |
| 2023-03-31 | $4.32M 10-Q · filed 2024-05-13 | $7.51M derived: sum of 2 quarters · filed 2024-05-13 | $11.43M derived: sum of 3 quarters · filed 2024-05-13 | ||
| 2022-12-31 | $3.19M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $7.11M derived: sum of 2 quarters · filed 2024-02-29 | $17.41M 10-K · filed 2024-02-29 | ||
| 2022-09-30 | $3.92M 10-Q · filed 2023-11-09 | $14.22M 10-Q · filed 2023-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OS Therapies Inc (OSTX) | United States | $0.076B | -2.17 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |